Skip to content



Page 4 of 8

  1. Content type: Original clinical investigation

    Obesity is currently regarded as a pro-inflammatory condition during which leptin (Ob gene product) might act as a risk factor for Cardiovascular Diseases (CVD) including Acute Myocardial Infarction (AMI). There ...

    Authors: Devarajan Nalini, Rajendran Karthick, Vijay Shirin, Ganesan Manohar and Raghunathan Malathi

    Citation: Thrombosis Journal 2015 13:12

    Published on:

  2. Content type: Reviewer acknowledgement

    The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 12 (2014) and whose valuable support is fundamental to its success.

    Authors: Yukio Ozaki and Hugo ten Cate

    Citation: Thrombosis Journal 2015 13:11

    Published on:

  3. Content type: Original clinical investigation

    Current clinical practice guidelines recommend the use of prophylactic doses of low molecular weight heparins for cancer patients requiring hospitalization for acute medical illness. However, a recently publis...

    Authors: Patricia Moretto, Junghyun Park, Marc Rodger, Grégoire Le Gal and Marc Carrier

    Citation: Thrombosis Journal 2015 13:10

    Published on:

  4. Content type: Review

    Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the prin...

    Authors: Herm Jan M Brinkman

    Citation: Thrombosis Journal 2015 13:9

    Published on:

  5. Content type: Case report

    Behçet’s disease (BD) is a rare vasculitis in sub-Saharan Africa. Vascular thrombosis, especially venous, is common in this condition and also constitutes a basic diagnostic criterion. Its affection of the sup...

    Authors: Simon Antoine Sarr, Pape Diadie Fall, Mouhamadou Chérif Mboup, Khadidiatou Dia, Malick Bodian and Modou Jobe

    Citation: Thrombosis Journal 2015 13:7

    Published on:

  6. Content type: Original clinical investigation

    Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment (SRI; ...

    Authors: Takeshi Fuji, Satoru Fujita, Yohko Kawai, Yasuyuki Abe, Tetsuya Kimura, Masayuki Fukuzawa, Kenji Abe and Shintaro Tachibana

    Citation: Thrombosis Journal 2015 13:6

    Published on:

  7. Content type: Original clinical investigation

    Ideal conditions for platelet reactivity testing are critical for optimal selection of a P2Y12 inhibitor. Data are inconsistent regarding the impact of high-fat meals on test assessment.

    Authors: Paul P Dobesh, Jamela F Urban, Scott W Shurmur and Julie H Oestreich

    Citation: Thrombosis Journal 2015 13:3

    Published on:

  8. Content type: Original clinical investigation

    The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for effica...

    Authors: Norikazu Yamada, Atsushi Hirayama, Hideaki Maeda, Satoru Sakagami, Hiroo Shikata, Martin H Prins, Anthonie WA Lensing, Masaharu Kato, Junichi Onuma, Yuki Miyamoto, Kazuma Iekushi and Mariko Kajikawa

    Citation: Thrombosis Journal 2015 13:2

    Published on:

    The Erratum to this article has been published in Thrombosis Journal 2016 14:11

  9. Content type: Case report

    Homocysteine is an amino acid that is toxic to vascular endothelial cells, and plasma elevations have been associated with venous thromboembolism. Severe hyperhomocysteinemia (>100 μmol/L) may result from muta...

    Authors: Zuhier Awan, Sumayah Aljenedil, David S Rosenblatt, Jean Cusson, Brian M Gilfix and Jacques Genest

    Citation: Thrombosis Journal 2014 12:30

    Published on:

  10. Content type: Review

    Mild therapeutic hypothermia is considered standard care in the treatment of patients resuscitated from cardiac arrest. With increasingly more frequent concomitant use of platelet-inhibiting drugs, clinicians ...

    Authors: Sven Van Poucke, Kris Stevens, Abraham Emanuel Marcus and Marcus Lancé

    Citation: Thrombosis Journal 2014 12:31

    Published on:

  11. Content type: Original clinical investigation

    In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of thes...

    Authors: Ashkan Labaf, Martin Carlwe and Peter J Svensson

    Citation: Thrombosis Journal 2014 12:29

    Published on:

  12. Content type: Original clinical investigation

    Venous thromboembolism (VTE) requires urgent diagnosis and treatment to avoid related complications. Clinical presentations of VTE are nonspecific and require definitive confirmation by imaging techniques. A c...

    Authors: Tarek Owaidah, Nahlah AlGhasham, Saad AlGhamdi, Dania AlKhafaji, Bandar ALAmro, Mohamed Zeitouni, Fawaz Skaff, Hazzaa AlZahrani, Adher AlSayed, Naser ElKum, Mahmoud Moawad, Ahmed Nasmi, Mohannad Hawari and Khalid Maghrabi

    Citation: Thrombosis Journal 2014 12:28

    Published on:

  13. Content type: Original clinical investigation

    Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban.

    Authors: Philip S Wells, Martin Gebel, Martin H Prins, Bruce L Davidson and Anthonie WA Lensing

    Citation: Thrombosis Journal 2014 12:26

    Published on:

  14. Content type: Original basic research

    Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of ora...

    Authors: Rupert M Bauersachs, Anthonie WA Lensing, Martin H Prins, Dagmar Kubitza, Ákos F Pap, Hervé Decousus, Jan Beyer-Westendorf and Paolo Prandoni

    Citation: Thrombosis Journal 2014 12:25

    Published on:

  15. Content type: Review

    Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

    Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier

    Citation: Thrombosis Journal 2014 12:24

    Published on:

  16. Content type: Review

    Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as eff...

    Authors: Vincent Geldhof, Christophe Vandenbriele, Peter Verhamme and Thomas Vanassche

    Citation: Thrombosis Journal 2014 12:21

    Published on:

  17. Content type: Original clinical investigation

    Warfarin is known for its interaction with many drugs, resulting in undesired treatment outcomes such as bleeding. The study aimed to assess the prevalence of drug-drug interactions and determinants of bleedin...

    Authors: Gebrehiwot Teklay, Nuredin Shiferaw, Befikadu Legesse and Mebratu Legesse Bekele

    Citation: Thrombosis Journal 2014 12:20

    Published on:

  18. Content type: Case report

    Enoxaparin displays fibrinolytic activity through stimulation of endothelial release of tissue plasminogen activator. Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibi...

    Authors: Gesa Wiegand, Vanya Icheva, Martin Schöning and Michael Hofbeck

    Citation: Thrombosis Journal 2014 12:19

    Published on:

  19. Content type: Original clinical investigation

    Erythropoietin (Epo) has been shown to improve myocardial function in models of experimental myocardial infarction, but has also been associated with a rise in thromboembolic events. Thus, the aim of this stud...

    Authors: Gabriele Demetz, Magdalena Laux, Armin Scherhag, Tiny Hoekstra, Marit M Suttorp, Friedo Dekker, Mark Roest, Mira Marcus-Kalish, Moshe Mittelman and Ilka Ott

    Citation: Thrombosis Journal 2014 12:18

    Published on:

  20. Content type: Original clinical investigation

    To evaluate the association between angiotensin I-converting enzyme insertion/deletion (ACE I/D) gene polymorphism and retinal vein occlusion (RVO). A total of 80 patients with retinal vein occlusion who was a...

    Authors: Işıl Kutluturk, Ali Karagöz, Tahir Bezgin, Vecih Oduncu, Ali Elveran, Cem Doğan, Ahmet Elbay, Cevat Kirma and Yusuf Özertürk

    Citation: Thrombosis Journal 2014 12:17

    Published on:

  21. Content type: Original clinical investigation

    Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulati...

    Authors: Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Verena Haupt, Jonas Schneider and Alexander GG Turpie

    Citation: Thrombosis Journal 2014 12:16

    Published on:

  22. Content type: Original clinical investigation

    Venous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to de...

    Authors: Fernando Vazquez, Ricardo Watman, Aldo Tabares, Carina Gumpel, Enrique Baldessari, Alicia B Vilaseca, Federico J Capparelli and Esteban Lifschitz

    Citation: Thrombosis Journal 2014 12:15

    Published on:

  23. Content type: Original clinical investigation

    Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent ...

    Authors: Elizabeth S Mearns, C Michael White, Christine G Kohn, Jessica Hawthorne, Ju-Sung Song, Joy Meng, Jeff R Schein, Monika K Raut and Craig I Coleman

    Citation: Thrombosis Journal 2014 12:14

    Published on:

  24. Content type: Original clinical investigation

    Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought ...

    Authors: Stuart G Nicholls, Jamie C Brehaut, Rubab G Arim, Kelly Carroll, Richard Perez, Kaveh G Shojania, Jeremy M Grimshaw and Roy M Poses

    Citation: Thrombosis Journal 2014 12:13

    Published on:

  25. Content type: Original clinical investigation

    Deep venous thrombosis (DVT), which is often associated with pulmonary embolism (PE), is a serious complication after total knee arthroplasty (TKA). In the present study, we examined the overall thrombotic and...

    Authors: Yukinori Tamura, Shigeshi Mori, Shigeki Asada, Naoyuki Kawao, Shigeru Ueshima, Hiroshi Kaji, Junichiro Yamamoto, Masao Akagi and Osamu Matsuo

    Citation: Thrombosis Journal 2014 12:11

    Published on:

  26. Content type: Original basic research

    Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kine...

    Authors: Joseph F Dwyer, Jill A McCoy, Ziping Yang, Michael Husser, Heinz Redl, Mary Ann Murphy, Martin Wolfsegger, James P DiOrio, Andreas Goppelt and Shane Donovan

    Citation: Thrombosis Journal 2014 12:10

    Published on:

  27. Content type: Original clinical investigation

    Venous thromboembolism (VTE) prophylaxis is underutilized for hospitalized patients. The primary objective of this study was to assess the impact of a continuing medical education (CME) program on thromboproph...

    Authors: Fahad Al-Hameed, Hasan M Al-Dorzi and Essam Aboelnazer

    Citation: Thrombosis Journal 2014 12:9

    Published on:

  28. Content type: Original clinical investigation

    New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in so...

    Authors: Raul Altman and Claudio Daniel Gonzalez

    Citation: Thrombosis Journal 2014 12:7

    Published on:

  29. Content type: Original clinical investigation

    Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, de...

    Authors: C Michael Dunham, Charlene Rabel, Barbara M Hileman, Jason Schiraldi, Elisha A Chance, Mark T Shima, Alddo A Molinar and David A Hoffman

    Citation: Thrombosis Journal 2014 12:4

    Published on:

  30. Content type: Reviewer acknowledgement

    The Editors of Thrombosis Journal would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).

    Authors: Yukio Ozaki and Hugo ten Cate

    Citation: Thrombosis Journal 2014 12:2

    Published on:

  31. Content type: Original basic research

    Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signa...

    Authors: Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario and Yoichi Sakata

    Citation: Thrombosis Journal 2014 12:1

    Published on:

  32. Content type: Review

    Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mor...

    Authors: Christopher Ward, Greg Conner, Geoffrey Donnan, Alexander Gallus and Simon McRae

    Citation: Thrombosis Journal 2013 11:27

    Published on:

  33. Content type: Case report

    Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preven...

    Authors: Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka and Hiroki Ishihara

    Citation: Thrombosis Journal 2013 11:26

    Published on:

  34. Content type: Original clinical investigation

    The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, i...

    Authors: Yuqi Wang, Chen Wang, Zhong Chen, Jiwei Zhang, Zhihong Liu, Bi Jin, Kejing Ying, Changwei Liu, Yuxia Shao, Zhicheng Jing, Isabelle Ling Meng, Martin H Prins, Ákos F Pap, Katharina Müller and Anthonie WA Lensing

    Citation: Thrombosis Journal 2013 11:25

    Published on:

  35. Content type: Original basic research

    Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma samples o...

    Authors: Klas Boeer, Leonid Cuznetov and Wolfgang Loesche

    Citation: Thrombosis Journal 2013 11:24

    Published on:

  36. Content type: Original basic research

    Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induce...

    Authors: Kaneo Satoh, Toshiya Hirayama, Katsuhiro Takano, Katsue Suzuki-Inoue, Tadashi Sato, Masato Ohta, Junko Nakagomi and Yukio Ozaki

    Citation: Thrombosis Journal 2013 11:23

    Published on:

  37. Content type: Case report

    Plasma protein-C exerts anticoagulatory effects by inactivating factors V and VIII. Hereditary protein C deficiency is transmitted as an autosomal dominant disorder. Homozygous individuals usually develop purp...

    Authors: Syed Maqbool, Vishal Rastogi, Ashok Seth, Satbir Singh, Vijay Kumar and Arif Mustaqueem

    Citation: Thrombosis Journal 2013 11:19

    Published on:

Official journal of

  • APSTH logo
  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

    Members of APSTH are entitled to a 15% discount on the article processing charge.

Annual Journal Metrics